Clinical-stage immunotherapy company ImmunityBio Inc (NASDAQ: IBRX) on Monday declared encouraging findings from the Patient-Reported Outcomes (PROs) in the QUILT 3.032 study for N-803 plus BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
These PROs indicate stable physical function and global health in participants, supporting the positive interim results where 71% of patients achieved a complete response.
The PROs, based on a 16 May 2022 data cutoff, revealed stability in physical function and global health in participants over the two-year study period. Those achieving a complete response with the novel combination therapy reported better physical function by month six compared to non-complete responders.
Combined with the positive response rates and a favorable safety profile, these findings support a beneficial risk-benefit ratio for N-803 plus BCG. The FDA is currently reviewing the Biologics License Application (BLA) for N-803 plus BCG, with a PDUFA date set for 23 April 2024.
The QUILT 3.032 study assesses the safety and efficacy of N-803 plus BCG in BCG-unresponsive NMIBC patients, addressing the need for a safe therapeutic option for this population.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment